Our CEO, Jak Knowles, joined a dynamic panel discussion titled, “The State of Bispecific and New Approaches in Development” alongside Zhen Su, MD MBA, CEO of Marengo Therapeutics, and Ramin Farzaneh-Far, CMO of Capstan Therapeutics. The conversation took place during the Goldman Sachs Cell Therapy Day event in #NewYork, moderated by Goldman Sachs Research team members Elizabeth W. and Paul Choi.
A special thanks to the Goldman Sachs research team for the kind invitation to join the Cell Therapy Day to showcase our Novel TCR Vbeta Bi-specific platform for precision in vivo T cell activation/expansion. Elizabeth W. Paul Choi Salveen Richter Chris Shibutani MD MBA Sonia Gupta Also, really nice to reconnect with peer companies who are also at the forefront of developing next wave T cell targeted technologies. Jak Knowles at Affini-T Therapeutics and Ramin Farzaneh-Far at Capstan Therapeutics. Marengo Therapeutics